Tandem Diabetes Care Inc (TNDM)
27.34
-1.25
(-4.37%)
USD |
NASDAQ |
Nov 15, 16:00
27.32
-0.02
(-0.07%)
After-Hours: 20:00
Tandem Diabetes Care Research and Development Expense (TTM): 189.28M for Sept. 30, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 189.28M |
| June 30, 2024 | 180.14M |
| March 31, 2024 | 173.75M |
| December 31, 2023 | 248.42M |
| September 30, 2023 | 241.40M |
| June 30, 2023 | 236.23M |
| March 31, 2023 | 226.86M |
| December 31, 2022 | 139.11M |
| September 30, 2022 | 133.02M |
| June 30, 2022 | 120.32M |
| March 31, 2022 | 107.25M |
| December 31, 2021 | 92.05M |
| September 30, 2021 | 79.94M |
| June 30, 2021 | 71.93M |
| March 31, 2021 | 67.42M |
| December 31, 2020 | 63.57M |
| September 30, 2020 | 58.76M |
| June 30, 2020 | 54.71M |
| March 31, 2020 | 49.93M |
| December 31, 2019 | 45.20M |
| September 30, 2019 | 41.43M |
| June 30, 2019 | 37.39M |
| March 31, 2019 | 32.64M |
| Date | Value |
|---|---|
| December 31, 2018 | 29.23M |
| September 30, 2018 | 26.18M |
| June 30, 2018 | 23.10M |
| March 31, 2018 | 21.51M |
| December 31, 2017 | 20.66M |
| September 30, 2017 | 19.26M |
| June 30, 2017 | 20.50M |
| March 31, 2017 | 19.77M |
| December 31, 2016 | 18.81M |
| September 30, 2016 | 18.60M |
| June 30, 2016 | 17.54M |
| March 31, 2016 | 17.27M |
| December 31, 2015 | 16.96M |
| September 30, 2015 | 16.75M |
| June 30, 2015 | 16.16M |
| March 31, 2015 | 15.99M |
| December 31, 2014 | 15.79M |
| September 30, 2014 | 15.22M |
| June 30, 2014 | 13.36M |
| March 31, 2014 | 12.42M |
| December 31, 2013 | 11.08M |
| September 30, 2013 | 9.722M |
| June 30, 2013 | 9.180M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
45.20M
Minimum
Dec 2019
248.42M
Maximum
Dec 2023
128.97M
Average
113.79M
Median
Research and Development Expense (TTM) Benchmarks
| Boston Scientific Corp | 1.519B |
| Masimo Corp | 183.10M |
| RxSight Inc | 32.50M |
| Perspective Therapeutics Inc | 28.53M |
| Xtant Medical Holdings Inc | 2.145M |